This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond
This week, we will discuss hopefully the final story of intensive BP lowering. BPROAD is a larger version of ACCORD without the glycemic control arm. Dive in.
This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?
This week, we discuss the latest from CRIC, an examination of NSAIDs versus opioids for patients with CKD. Join us May 12 and 13th to discuss with #NephJC.
In conjunction with NephMadness - Pain Region discussion, we discuss a recent JAMA Network Open study, reporting higher kidney risk in young men taking NSAIDs.
There is AKI. You are ready to discharge the patient. Should you restart their ACEI/ARB? Or they were never on an ACEI/ARB - but surely with a history of heart failure, they should be on one? How do you decide? Join us to discuss some exciting new data
This week, we will discuss an observational study - a very large series of using DDAVP for treatment of hyponatremia. Yes, you read that right. Read the paper for free thanks to Am J Med and join us on March 27/28 to discuss.